HistoSonics, developer of the Edison® Histotripsy System and histotripsy therapy platforms, has completed a new financing round with participation from Yosemite, led by Reed Jobs, along with several new strategic investors. Financial details of the investment were not disclosed.

The funding follows a period of strong growth for the company as it expands the clinical use of histotripsy for liver tumours worldwide and advances additional applications of its non-invasive technology across a range of solid tumours.

HistoSonics stated that the new investors bring strategic support and share the company’s goal of improving outcomes for patients while creating long-term value for healthcare providers and stakeholders.

Over the past year, the company has increased the commercial and clinical adoption of histotripsy for the treatment of liver tumours, including metastatic disease. The technology is being used more widely at leading academic medical centres and healthcare systems. HistoSonics recently submitted a De Novo request to the U.S. Food and Drug Administration (FDA) seeking clearance for the treatment of kidney tumours, which could significantly expand the use of the platform.

The company is also reporting encouraging clinical progress in the treatment of primary pancreatic tumours, an area with limited treatment options. HistoSonics is working towards a future FDA submission for pancreatic applications as development milestones continue to be achieved.

Yosemite, which focuses on supporting technologies that can improve patient outcomes, invested in HistoSonics due to the potential of histotripsy to transform the treatment of some of the most challenging cancers and diseases.

Histotripsy is a non-invasive treatment that uses focused ultrasound energy and acoustic cavitation to mechanically destroy targeted tissue without the need for surgery or radiation. The Edison Histotripsy System has received FDA De Novo clearance for the destruction of liver tumours and is seeing growing adoption in the United States and international markets. Applications beyond liver tumours remain investigational.

The proceeds from the financing will be used to support commercial expansion, clinical development programmes, regulatory activities and the continued advancement of HistoSonics’ product pipeline.

 

Source: businesswire.com

Report Abuse